$900,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program. Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia. Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit."
You can find more data on corporate lobbying on Quiver Quantitative.
NBIX Congressional Stock Trading
Members of Congress have traded $NBIX stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/11 and 1 sale worth up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
NBIX Insider Trading Activity
NBIX insiders have traded $NBIX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KEVIN CHARLES GORMAN has made 0 purchases and 2 sales selling 115,935 shares for an estimated $14,597,491.
- JUDE ONYIA (Chief Scientific Officer) has made 0 purchases and 2 sales selling 80,181 shares for an estimated $10,453,425.
- WILLIAM H RASTETTER sold 30,000 shares for an estimated $3,305,952
- INGRID DELAET (Chief Regulatory Officer) sold 457 shares for an estimated $61,695
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NBIX Hedge Fund Activity
We have seen 292 institutional investors add shares of NBIX stock to their portfolio, and 282 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,727,629 shares (-11.8%) from their portfolio in Q2 2025, for an estimated $217,145,689
- JPMORGAN CHASE & CO added 1,590,749 shares (+59.6%) to their portfolio in Q2 2025, for an estimated $199,941,241
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,546,856 shares (+100.5%) to their portfolio in Q2 2025, for an estimated $194,424,330
- CITADEL ADVISORS LLC added 1,160,047 shares (+130.5%) to their portfolio in Q2 2025, for an estimated $145,806,307
- RTW INVESTMENTS, LP added 1,062,072 shares (+inf%) to their portfolio in Q2 2025, for an estimated $133,491,829
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 844,912 shares (-42.0%) from their portfolio in Q2 2025, for an estimated $106,196,989
- LOS ANGELES CAPITAL MANAGEMENT LLC added 740,842 shares (+19454.9%) to their portfolio in Q2 2025, for an estimated $93,116,430
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NBIX Analyst Ratings
Wall Street analysts have issued reports on $NBIX in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 09/22/2025
- Morgan Stanley issued a "Overweight" rating on 09/05/2025
- Guggenheim issued a "Buy" rating on 08/01/2025
- Stifel issued a "Buy" rating on 07/31/2025
- Wedbush issued a "Outperform" rating on 07/31/2025
- Piper Sandler issued a "Overweight" rating on 07/31/2025
- RBC Capital issued a "Outperform" rating on 07/31/2025
To track analyst ratings and price targets for NBIX, check out Quiver Quantitative's $NBIX forecast page.
NBIX Price Targets
Multiple analysts have issued price targets for $NBIX recently. We have seen 14 analysts offer price targets for $NBIX in the last 6 months, with a median target of $169.0.
Here are some recent targets:
- Jeffrey Hung from Morgan Stanley set a target price of $168.0 on 10/20/2025
- Ashwani Verma from UBS set a target price of $195.0 on 10/09/2025
- Ami Fadia from Needham set a target price of $170.0 on 09/22/2025
- Brian Abrahams from RBC Capital set a target price of $149.0 on 09/05/2025
- Yatin Suneja from Guggenheim set a target price of $175.0 on 08/01/2025
- David Amsellem from Piper Sandler set a target price of $175.0 on 07/31/2025
- Anupam Rama from JP Morgan set a target price of $145.0 on 07/31/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
